File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Candida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen

TitleCandida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen
Authors
Issue Date1994
PublisherSociety for General Microbiology. The Journal's web site is located at http://jmm.sgmjournals.org
Citation
Journal Of Medical Microbiology, 1994, v. 41 n. 5, p. 295-310 How to Cite?
AbstractEarly reports of Candida krusei in man describe the organism as a transient, infrequent isolate of minor clinical significance inhabiting the mucosal surfaces. More recently it has emerged as a notable pathogen with a spectrum of clinical manifestations such as fungaemia, endophthalmitis, arthritis and endocarditis, most of which usually occur in compromised patient groups in a nosocomial setting. The advent of human immunodeficiency virus infection and the widespread use of the newer triazole fluconazole to suppress fungal infections in these patients have contributed to a significant increase in C. krusei infection, particularly because of the high incidence of resistance of the yeast to this drug. Experimental studies have generally shown C. krusei to be less virulent than C. albicans in terms of its adherence to both epithelial and prosthetic surfaces, proteolytic potential and production of phospholipases. Furthermore, it would seem that C. krusei is significantly different from other medically important Candida spp. in its structural and metabolic features, and exhibits different behaviour patterns towards host defences, adding credence to the belief that it should be re-assigned taxonomically. An increased awareness of the pathogenic potential of this yeast coupled with the newer molecular biological approaches to its study may facilitate the continued exploration of the epidemiology and pathogenesis of C. krusei infections.
Persistent Identifierhttp://hdl.handle.net/10722/66411
ISSN
2015 Impact Factor: 2.269
2015 SCImago Journal Rankings: 1.060
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSamaranayake, YHen_HK
dc.contributor.authorSamaranayake, LPen_HK
dc.date.accessioned2010-09-06T05:46:08Z-
dc.date.available2010-09-06T05:46:08Z-
dc.date.issued1994en_HK
dc.identifier.citationJournal Of Medical Microbiology, 1994, v. 41 n. 5, p. 295-310en_HK
dc.identifier.issn0022-2615en_HK
dc.identifier.urihttp://hdl.handle.net/10722/66411-
dc.description.abstractEarly reports of Candida krusei in man describe the organism as a transient, infrequent isolate of minor clinical significance inhabiting the mucosal surfaces. More recently it has emerged as a notable pathogen with a spectrum of clinical manifestations such as fungaemia, endophthalmitis, arthritis and endocarditis, most of which usually occur in compromised patient groups in a nosocomial setting. The advent of human immunodeficiency virus infection and the widespread use of the newer triazole fluconazole to suppress fungal infections in these patients have contributed to a significant increase in C. krusei infection, particularly because of the high incidence of resistance of the yeast to this drug. Experimental studies have generally shown C. krusei to be less virulent than C. albicans in terms of its adherence to both epithelial and prosthetic surfaces, proteolytic potential and production of phospholipases. Furthermore, it would seem that C. krusei is significantly different from other medically important Candida spp. in its structural and metabolic features, and exhibits different behaviour patterns towards host defences, adding credence to the belief that it should be re-assigned taxonomically. An increased awareness of the pathogenic potential of this yeast coupled with the newer molecular biological approaches to its study may facilitate the continued exploration of the epidemiology and pathogenesis of C. krusei infections.en_HK
dc.languageengen_HK
dc.publisherSociety for General Microbiology. The Journal's web site is located at http://jmm.sgmjournals.orgen_HK
dc.relation.ispartofJournal of Medical Microbiologyen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntifungal Agents - pharmacology - therapeutic useen_HK
dc.subject.meshCandida - drug effects - growth & development - pathogenicityen_HK
dc.subject.meshCandidiasis - drug therapy - epidemiology - microbiologyen_HK
dc.subject.meshEndophthalmitis - drug therapy - epidemiology - microbiologyen_HK
dc.subject.meshEye Infections, Fungal - drug therapy - epidemiology - microbiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshVirulenceen_HK
dc.titleCandida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-2615&volume=41&spage=295&epage=310&date=1994&atitle=Candida+krusei:+biology,+epidemiology,+pathogenicity+and+clinical+manifestations+of+an+emerging+pathogenen_HK
dc.identifier.emailSamaranayake, YH:hema@hkucc.hku.hken_HK
dc.identifier.emailSamaranayake, LP:lakshman@hku.hken_HK
dc.identifier.authoritySamaranayake, YH=rp00025en_HK
dc.identifier.authoritySamaranayake, LP=rp00023en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7966200-
dc.identifier.scopuseid_2-s2.0-0027959785en_HK
dc.identifier.hkuros3548en_HK
dc.identifier.volume41en_HK
dc.identifier.issue5en_HK
dc.identifier.spage295en_HK
dc.identifier.epage310en_HK
dc.identifier.isiWOS:A1994PQ83900002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridSamaranayake, YH=6602677237en_HK
dc.identifier.scopusauthoridSamaranayake, LP=7102761002en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats